NO20080484L - Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder - Google Patents

Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder

Info

Publication number
NO20080484L
NO20080484L NO20080484A NO20080484A NO20080484L NO 20080484 L NO20080484 L NO 20080484L NO 20080484 A NO20080484 A NO 20080484A NO 20080484 A NO20080484 A NO 20080484A NO 20080484 L NO20080484 L NO 20080484L
Authority
NO
Norway
Prior art keywords
compounds
receptor antagonists
treatment methods
preparations containing
niacin receptor
Prior art date
Application number
NO20080484A
Other languages
English (en)
Norwegian (no)
Inventor
Subharekha Raghavan
Steven L Colletti
Fa-Xiang Ding
Hong Shen
James R Tata
Ashley Rouse Lins
Abigail Lee Smenton
Weichun Chen
Darby Rye Schmidt
George Scott Tria
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20080484L publication Critical patent/NO20080484L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/52—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20080484A 2005-06-28 2008-01-25 Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder NO20080484L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69471105P 2005-06-28 2005-06-28
PCT/US2006/024740 WO2007002557A1 (en) 2005-06-28 2006-06-26 Niacin receptor agonists, compositions containing such compounds and methods of treatment

Publications (1)

Publication Number Publication Date
NO20080484L true NO20080484L (no) 2008-03-28

Family

ID=37134234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080484A NO20080484L (no) 2005-06-28 2008-01-25 Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder

Country Status (31)

Country Link
US (3) US8168649B2 (es)
EP (1) EP1901731B1 (es)
JP (1) JP5113046B2 (es)
KR (1) KR20080019653A (es)
CN (1) CN101208082A (es)
AR (1) AR057408A1 (es)
AT (1) ATE499932T1 (es)
AU (1) AU2006261839B2 (es)
BR (1) BRPI0612117A2 (es)
CA (1) CA2611552A1 (es)
CR (1) CR9589A (es)
CY (1) CY1112019T1 (es)
DE (1) DE602006020447D1 (es)
DK (1) DK1901731T3 (es)
EC (1) ECSP078018A (es)
ES (1) ES2360726T3 (es)
HR (1) HRP20110295T1 (es)
IL (1) IL188329A0 (es)
MA (1) MA29647B1 (es)
MX (1) MX2008000113A (es)
MY (1) MY141024A (es)
NI (1) NI200700319A (es)
NO (1) NO20080484L (es)
PE (2) PE20070097A1 (es)
PL (1) PL1901731T3 (es)
PT (1) PT1901731E (es)
RU (1) RU2008102936A (es)
SI (1) SI1901731T1 (es)
TW (1) TWI313258B (es)
WO (1) WO2007002557A1 (es)
ZA (1) ZA200710645B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
WO2007002557A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US20090258862A1 (en) * 2005-08-29 2009-10-15 Colletti Steven L Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007092364A2 (en) * 2006-02-07 2007-08-16 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
US20070238746A1 (en) 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
JP4903914B2 (ja) 2008-07-02 2012-03-28 スリーエム イノベイティブ プロパティズ カンパニー 低表面エネルギー接着剤
SI2308838T1 (sl) * 2008-07-08 2016-09-30 Daiichi Sankyo Company, Limited Dušik vsebujoča aromatska heterociklična spojina
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2012068096A2 (en) 2010-11-15 2012-05-24 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2012152741A1 (de) 2011-05-10 2012-11-15 Bayer Intellectual Property Gmbh Bicyclische (thio)carbonylamidine
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
MX2015002555A (es) 2012-08-30 2015-06-23 Nippon Shinyaku Co Ltd Derivado de piridina y medicina.
CN108290840A (zh) 2015-12-01 2018-07-17 巴斯夫欧洲公司 作为杀真菌剂的吡啶化合物
BR112018010140A8 (pt) 2015-12-01 2019-02-26 Basf Se compostos de fórmula, composição, utilização de um composto de fórmula, método para o combate de fungos fitopatogênicos e semente
US11737463B2 (en) 2017-05-30 2023-08-29 Basf Se Pyridine and pyrazine compounds
CN113563166B (zh) * 2019-04-24 2023-08-01 珠海市柏瑞医药科技有限公司 一种香兰醇醚的合成方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2153777A1 (en) 1993-01-15 1994-07-21 Siegfried H. Reich Hiv protease inhibitors
EP1007563A4 (en) 1997-06-12 2003-04-16 Smithkline Beecham Corp HM74A RECEPTOR
EP1033983A1 (en) * 1997-11-24 2000-09-13 Merck & Co., Inc. Cyclic amino acid derivatives as cell adhesion inhibitors
IT1309593B1 (it) 1999-03-05 2002-01-24 Novuspharma Spa Composti eterociclici ad attivita' antitumorale.
AU782959B2 (en) 1999-11-17 2005-09-15 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human G protein-coupled receptors
EP1272631A2 (en) 2000-04-05 2003-01-08 Bayer Aktiengesellschaft Regulation of human hm74-like g protein coupled receptor
EP1377834A2 (en) 2001-04-11 2004-01-07 Glaxo Group Limited Medicaments which are modulators of hm74 and/or hm74a activity
AUPR738301A0 (en) 2001-08-30 2001-09-20 Starpharma Limited Chemotherapeutic agents
US6902902B2 (en) * 2001-11-27 2005-06-07 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors and modulators thereof for the treatment of metabolic-related disorders
JP2005170790A (ja) * 2002-01-09 2005-06-30 Ajinomoto Co Inc Ｎ−アルキルスルフォニル置換アミド誘導体
PL374860A1 (en) * 2002-07-09 2005-11-14 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
EP1781657B1 (en) 2004-02-14 2013-03-27 GlaxoSmithKline Intellectual Property Development Limited Medicaments with hm74a receptor activity
CA2557541C (en) * 2004-02-26 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyrimidine derivatives
EP1805180A1 (en) 2004-10-22 2007-07-11 SmithKline Beecham Corporation Xanthine derivatives with hm74a receptor activity
CN101056635A (zh) * 2004-11-04 2007-10-17 默克公司 烟酸受体激动剂、含有该化合物的组合物及治疗方法
AU2005309737A1 (en) * 2004-11-23 2006-06-01 Merck Sharp & Dohme Corp. Niacin receptor agonists, compositions containing such compounds and methods of treatment
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
GB0503053D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503056D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
GB0503054D0 (en) 2005-02-14 2005-03-23 Smithkline Beecham Corp Chemical compounds
EP1848699A1 (en) 2005-02-14 2007-10-31 Smithkline Beecham Corporation Anthranilic acid derivatives as hm74a receptor agonists
BRPI0610133A2 (pt) 2005-05-17 2010-06-01 Schering Corp heterociclos como agonistas de receptor de ácido nicotìnico para o tratamento de dislipidemia
KR100955112B1 (ko) * 2005-06-14 2010-04-28 에프. 호프만-라 로슈 아게 안트라닐산 유도체
WO2007002557A1 (en) 2005-06-28 2007-01-04 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment

Also Published As

Publication number Publication date
JP2009501155A (ja) 2009-01-15
ES2360726T3 (es) 2011-06-08
PE20070097A1 (es) 2007-03-08
US8168649B2 (en) 2012-05-01
CA2611552A1 (en) 2007-01-04
PE20110541A1 (es) 2011-08-04
EP1901731A1 (en) 2008-03-26
TW200726739A (en) 2007-07-16
ATE499932T1 (de) 2011-03-15
US20100144778A1 (en) 2010-06-10
EP1901731B1 (en) 2011-03-02
IL188329A0 (en) 2008-04-13
CN101208082A (zh) 2008-06-25
HRP20110295T1 (hr) 2011-05-31
NI200700319A (es) 2008-05-12
US20060293364A1 (en) 2006-12-28
CY1112019T1 (el) 2015-11-04
SI1901731T1 (sl) 2011-07-29
MA29647B1 (fr) 2008-07-01
US20120178750A1 (en) 2012-07-12
TWI313258B (en) 2009-08-11
ECSP078018A (es) 2008-01-23
KR20080019653A (ko) 2008-03-04
ZA200710645B (en) 2008-08-27
JP5113046B2 (ja) 2013-01-09
PL1901731T3 (pl) 2011-08-31
CR9589A (es) 2008-04-10
DE602006020447D1 (de) 2011-04-14
DK1901731T3 (da) 2011-06-14
AR057408A1 (es) 2007-12-05
MX2008000113A (es) 2008-03-18
AU2006261839B2 (en) 2011-09-01
PT1901731E (pt) 2011-05-11
BRPI0612117A2 (pt) 2012-09-04
AU2006261839A1 (en) 2007-01-04
RU2008102936A (ru) 2009-08-10
MY141024A (en) 2010-02-25
WO2007002557A1 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
NO20080484L (no) Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder
WO2007120575A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NO20073664L (no) Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
NO20082088L (no) Azetidiner som MEK-inhibitorer for behandling av proliferative sykdommer
WO2007092364A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NO20060001L (no) Nye P2X7-reseptorantagonister og deres anvendelse
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
NO20052474L (no) Amort form av esomeprazolsalter
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
NO20091395L (no) Nye tiofenderivater
NO20066055L (no) Pyridinderivater
NO20076635L (no) Krystallinske og andre former for 4-amino-5-fluor-3-[6-(4-metylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-kinolin-2-on-melkesyresalter
NO20091734L (no) Glucagonreseptorantagonistforbindelser, preparater inneholdende slike forbindelser, og metoder for anvendelse
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
NO20093146L (no) Amino-pyridinderivater som S1P1/EDG1-reseptoragonister
NO20083630L (no) Nye pyridinderivater
NO20082445L (no) Neuropeptid-2 reseptor-agonister
WO2008051403A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
HK1119699A1 (en) Pyridopyrimidinone inhibitors of pi3kalpha
NO20060717L (no) Sykliske derivater som modulatorer av kjemokin reseptoractivitet
NO20052739D0 (no) CCR5-antagonister som medikamenter
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
HK1120442A1 (en) Novel opioid antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application